Tech Company Financing Transactions
HexemBio Funding Round
HexemBio secured a $10.4 million Seed financing round on 4/6/2026. Investors included Draper Associates, Seraphim Capital and SOSV.
Transaction Overview
Company Name
Announced On
4/6/2026
Transaction Type
Venture Equity
Amount
$10,400,000
Round
Seed
Investors
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
7 Pennsylvania Plaza, 9th Floor
New York, NY 10001
USA
New York, NY 10001
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
HexemBio is developing regenerative therapies based on the Synthetic Human Yolk Sac, a technology designed to rejuvenate aging blood stem cells by recreating the developmental environment where they first arise. By restoring the regenerative capacity of a patient's own hematopoietic stem cells, HexemBio aims to improve outcomes in bone marrow transplantation and unlock new approaches to extending human healthspan. The company received FDA Orphan Drug Designation in July 2025 and completed its FDA Pre-IND meeting in January 2026. Founded in 2024, HexemBio operates from New York City and from Berkeley.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Gabriel Tremblay
Chief Scientific Officer
Mo EbrahimkhaNI
Chief Technical Officer
Samira Kiani
Co-Founder
Joshua Hislop
VP - Bus. Development
Samet Yildirim
Browse more venture capital transactions:
Prev: 4/6/2026: Sora Fuel venture capital transaction
Next: 4/6/2026: SatLeo Labs venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on all VC transactions involving tech companies. All VC database entries on this site are derived from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs